Description of Medical ServiceThe assay provides a 50 gene profile that is used to assess the prognosis and predict response to treatment of breast cancer patients. The Risk of Recurrence (ROR) score is based on the identification of the four intrinsic breast cancer subtypes, Luminal A, Luminal B, HER2-enriched, and Basal-like. The unique genetic profile is produced using a diagnostic kit which quantifies mRNA expression and can be performed in local laboratories provided they have the NanoString nCounter® Dx technology (Prosigna enabled).
Description of Medical ConditionProsigna® is a 50-gene test that is designed to identify intrinsic breast cancer subtypes and to generate a Risk of Recurrence (ROR) score. This is then used to tailor the most appropriate therapy for that type of primary breast cancer. It will be used for women with HER2 –ve, ER and/or PR +ve breast cancer who do not have clear cut treatment choices.
Reason for ApplicationNew Application
Medical Service TypeTherapeutic
Previous Application NumberNot Applicable
Application FormApplication Form (PDF 428 KB)
Application Form (Word 175 KB)
Consultation SurveyConsultation Survey (PDF 97 KB)
Consultation Survey (Word 508 KB)
Public Summary DocumentPublic Summary Document (PDF 352 KB)
Public Summary Document (Word 136 KB)